Drug intelligence / Profile preview

lisaftoclax + cytarabine

Development stage: Unknown
Lead developer: Ascentage Pharma
Modality: Small Molecules
Administration: Oral, Intravenous, Subcutaneous

Overview

Lisaftoclax + cytarabine is an investigational combination regimen consisting of lisaftoclax (APG-2575), a selective small-molecule inhibitor of B-cell lymphoma 2 (BCL-2), and cytarabine, a pyrimidine nucleoside analog chemotherapy agent. Lisaftoclax functions by binding to BCL-2, thereby displacing pro-apoptotic proteins and inducing apoptosis in cancer cells that depend on BCL-2 for survival. Cytarabine interferes with DNA synthesis by being incorporated into DNA and inhibiting DNA polymerase. This combination is primarily being evaluated as a consolidation therapy for young adults with newly diagnosed intermediate- and high-risk acute myeloid leukemia (AML) who have achieved complete response following induction therapy.

Other names: lisaftoclax + Ara-C

Targets

RNAP (Bacterial dna-dependent RNA polymerase)RNR (Ribonucleotide reductase)BCL-2 (BCL-2 family)DNADNA polymerase family

Beyond the preview

Go deeper on lisaftoclax + cytarabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lisaftoclax + cytarabine.

Explore the full profile